| pubmed-article:21292026 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21292026 | lifeskim:mentions | umls-concept:C0040558 | lld:lifeskim |
| pubmed-article:21292026 | lifeskim:mentions | umls-concept:C0040556 | lld:lifeskim |
| pubmed-article:21292026 | lifeskim:mentions | umls-concept:C0240339 | lld:lifeskim |
| pubmed-article:21292026 | lifeskim:mentions | umls-concept:C0032659 | lld:lifeskim |
| pubmed-article:21292026 | lifeskim:mentions | umls-concept:C0036341 | lld:lifeskim |
| pubmed-article:21292026 | lifeskim:mentions | umls-concept:C0205251 | lld:lifeskim |
| pubmed-article:21292026 | lifeskim:mentions | umls-concept:C0007328 | lld:lifeskim |
| pubmed-article:21292026 | lifeskim:mentions | umls-concept:C0600367 | lld:lifeskim |
| pubmed-article:21292026 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:21292026 | pubmed:dateCreated | 2011-4-13 | lld:pubmed |
| pubmed-article:21292026 | pubmed:abstractText | There are conflicting reports concerning the association of Toxoplasma gondii infection and schizophrenia in humans. Therefore, we determined such association in a Mexican population of Mestizo ethnicity. Through a case-control study design, 50 schizophrenic patients and 150 control subjects matched by gender, age, residence place, and ethnicity were examined with enzyme-linked immunoassays for the presence and levels of T. gondii IgG antibodies and for the presence of T. gondii IgM antibodies. Schizophrenic patients attended a public psychiatric hospital in Durango City, Mexico, and the control group consisted of individuals of the general population of the same city. Socio-demographic, clinical and behavioral characteristics from the study subjects were also obtained. Both the seroprevalence and the level of T.gondii IgG antibodies were higher in schizophrenic patients (10/50; 20%) than in control subjects (8/150; 5.3%) (OR=4.44; 95% CI: 1.49-13.37; P=0.003). The IgG T. gondii levels higher than 150 IU/ml were more frequently observed in patients than in controls (10% versus 2%, respectively; P=0.02). One (50%) of the two patients with recently diagnosed schizophrenia and none of the controls had T. gondii IgM antibodies (P=0.01). T. gondii seropositivity was significantly higher in patients with a history of cleaning cat excrement (P=0.005), and suffering from simple schizophrenia (ICD-10 classification: F20.6) (P=0.03) than patients without these characteristics. Toxoplasma seroprevalence was also significantly higher in patients with simple schizophrenia (F20.6) than in those with paranoid schizophrenia (F20.0) (P=0.02). This study provides elements to clarify the controversial information on the association of T. gondii infection and schizophrenia. | lld:pubmed |
| pubmed-article:21292026 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21292026 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21292026 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21292026 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21292026 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21292026 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21292026 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21292026 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:21292026 | pubmed:issn | 1873-0329 | lld:pubmed |
| pubmed-article:21292026 | pubmed:author | pubmed-author:LiesenfeldOli... | lld:pubmed |
| pubmed-article:21292026 | pubmed:author | pubmed-author:DubeyJitender... | lld:pubmed |
| pubmed-article:21292026 | pubmed:author | pubmed-author:Alvarado-Esqu... | lld:pubmed |
| pubmed-article:21292026 | pubmed:author | pubmed-author:Estrada-Martí... | lld:pubmed |
| pubmed-article:21292026 | pubmed:author | pubmed-author:Torres-Castor... | lld:pubmed |
| pubmed-article:21292026 | pubmed:author | pubmed-author:Urbina-Álvare... | lld:pubmed |
| pubmed-article:21292026 | pubmed:author | pubmed-author:Molotla-de-Le... | lld:pubmed |
| pubmed-article:21292026 | pubmed:copyrightInfo | Published by Elsevier Ireland Ltd. | lld:pubmed |
| pubmed-article:21292026 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21292026 | pubmed:volume | 60 | lld:pubmed |
| pubmed-article:21292026 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21292026 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21292026 | pubmed:pagination | 151-5 | lld:pubmed |
| pubmed-article:21292026 | pubmed:meshHeading | pubmed-meshheading:21292026... | lld:pubmed |
| pubmed-article:21292026 | pubmed:meshHeading | pubmed-meshheading:21292026... | lld:pubmed |
| pubmed-article:21292026 | pubmed:meshHeading | pubmed-meshheading:21292026... | lld:pubmed |
| pubmed-article:21292026 | pubmed:meshHeading | pubmed-meshheading:21292026... | lld:pubmed |
| pubmed-article:21292026 | pubmed:meshHeading | pubmed-meshheading:21292026... | lld:pubmed |
| pubmed-article:21292026 | pubmed:meshHeading | pubmed-meshheading:21292026... | lld:pubmed |
| pubmed-article:21292026 | pubmed:meshHeading | pubmed-meshheading:21292026... | lld:pubmed |
| pubmed-article:21292026 | pubmed:meshHeading | pubmed-meshheading:21292026... | lld:pubmed |
| pubmed-article:21292026 | pubmed:meshHeading | pubmed-meshheading:21292026... | lld:pubmed |
| pubmed-article:21292026 | pubmed:meshHeading | pubmed-meshheading:21292026... | lld:pubmed |
| pubmed-article:21292026 | pubmed:meshHeading | pubmed-meshheading:21292026... | lld:pubmed |
| pubmed-article:21292026 | pubmed:meshHeading | pubmed-meshheading:21292026... | lld:pubmed |
| pubmed-article:21292026 | pubmed:meshHeading | pubmed-meshheading:21292026... | lld:pubmed |
| pubmed-article:21292026 | pubmed:meshHeading | pubmed-meshheading:21292026... | lld:pubmed |
| pubmed-article:21292026 | pubmed:meshHeading | pubmed-meshheading:21292026... | lld:pubmed |
| pubmed-article:21292026 | pubmed:meshHeading | pubmed-meshheading:21292026... | lld:pubmed |
| pubmed-article:21292026 | pubmed:meshHeading | pubmed-meshheading:21292026... | lld:pubmed |
| pubmed-article:21292026 | pubmed:meshHeading | pubmed-meshheading:21292026... | lld:pubmed |
| pubmed-article:21292026 | pubmed:meshHeading | pubmed-meshheading:21292026... | lld:pubmed |
| pubmed-article:21292026 | pubmed:meshHeading | pubmed-meshheading:21292026... | lld:pubmed |
| pubmed-article:21292026 | pubmed:meshHeading | pubmed-meshheading:21292026... | lld:pubmed |
| pubmed-article:21292026 | pubmed:meshHeading | pubmed-meshheading:21292026... | lld:pubmed |
| pubmed-article:21292026 | pubmed:meshHeading | pubmed-meshheading:21292026... | lld:pubmed |
| pubmed-article:21292026 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21292026 | pubmed:articleTitle | Toxoplasma gondii infection and schizophrenia: a case control study in a low Toxoplasma seroprevalence Mexican population. | lld:pubmed |
| pubmed-article:21292026 | pubmed:affiliation | Faculty of Medicine, Juárez University of Durango State, Avenida Universidad S/N esquina Fanny Anitua, 34000 Durango, Dgo, Mexico. alvaradocosme@yahoo.com | lld:pubmed |
| pubmed-article:21292026 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21292026 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:21292026 | lld:pubmed |
